35 results about "Paramyxoviridae" patented technology

Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.

The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate having the structure:for use in treating viral infections. One crystalline form of the compound can be characterized by an X-ray powder diffraction (XRPD) pattern having peaks at 22.3°, 16.9°, and 16.2° 2-θ±0.2° 2-θ. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.

Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably adsorbs the phenolic compounds but does not retain polar non-phenolic compounds, wherein the resin comprises aromatic rings substituted with one or more electron-withdrawing groups. This invention also includes compositions enriched in phenolic compounds. This invention encompasses methods of using the phenolic-enriched compositions for treating warm-blooded animals, including humans, infected with paramyxovaridae such as respiratory syncytial virus, orthomyoxovaridae such as influenza A, B, and C, parainfluenza, Herpes viruses such as HSV-1 and HSV-2, and Flaviviruses such as West Nile Virus, and for treating inflammation such as caused by arthritis, stress and digestive disease. The compositions are also useful as meat additives to inhibit food-borne pathogens.

A compound or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to a virus of the Paramyxoviridae or Orthomyxoviridae family, or other disorders, in particular respiratory syncytial virus, more fully described herein.

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

The present invention provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing thetarget cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.

Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

This invention provides a process for the preparation of compositions enriched in total phenols from a crude plant extract. The process includes a novel column purification step using a brominated polystyrene resin. This invention also includes compositions enriched in total phenols. The enriched compositions are characterized as containing monomeric, oligomeric and polymeric phenols and having HPLC chromatograms substantially as set forth in FIGS. 10-13. This invention encompasses methods of using the total phenol-enriched compositions for treating warm-blooded animals, including humans, infected with paramyxovaridae such as respiratory syncytial virus, orthomyoxovaridae such as influenza A, B, and C, parainfluenza, Herpes viruses such as HSV-1 and HSV-2, and Flaviviruses such as West Nile Virus, and for treating inflammation such as caused by arthritis, stress and digestive disease.

The invention provides recombinant viruses comprising heterologous envelope proteins capable of mediating entry of the recombinant viruses into host cells. In one embodiment, a recombinant virus of the invention is a member of the Paramyx-ovirzdae family (e.g., a respiratory syncytial virus), and the heterologous envelope protein includes the ectodomain of a baculovirus envelope protein (e.g., the GP64 protein). In some cases, the heterologous envelope protein is provided in addition to homologous envelope proteins) which may or may not be functional. The heterologous protein can provide the recombinant virus with enhanced stability (e.g., at 4° C., 22° C., or 37° C.), and allows production of high-titer virus stocks. The heterologous protein can also impart temperature sensitivity to the replication of the recombinant virus. In addition, the recombinant virus can be designed to be infectious but incapable of spreading between host cells by providing the heterologous protein by complementation in trans. These features attenuate the disease-causing potential of the recombinant virus, therefore increasing its safety of use as vaccines.

A compound or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to a virus of the Paramyxoviridae or Orthomyxoviridae family, or other disorders, in particular respiratory syncytial virus, more fully described herein.

The present invention relates to the use of the antiviral activity of exogenous leukotriene B4 (LTB4), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal enveloped RNA viruses. The human and animal enveloped RNA viruses are RNA viruses, such as togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, filoviridae, arenaviridae, bunyaviridae, rhabdoviridae and flaviviridae in general, and Retroviridae such as HIV-1 and HIV-2.

Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins anf for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.

A virus vector contains a genome that is derived from a virus belonging to the family Paramyxoviridae, and has a gene encoding a modified H protein, a gene encoding a modified F protein, and foreign genes. The genome may be segmented into multiple segments, and each genome segment may have a leader sequence and a trailer sequence.

The present invention relates to the field of (vector) vaccines, and especially to an enhanced arrangement of nucleotide sequences for expressing a Paramyxoviridae virus containing an exogenous gene of interest. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

The present invention provides a method for optimized preparation of an inactivated vaccine and / or an attenuated live vaccine, wherein in host cells, the cancer inhibition candidate gene 2 of glioma is subjected to over-expression to optimize the inside-host-cell replication environment for preparing the inactivated vaccine and / or attenuated live vaccine so as to improve the titers of 4 categories of viruses (including coronavirus, Paramyxoviridae, Orthomyxoviridae and herpes virus) by 1-3 lg unit. According to the present invention, the new strategy and the feasible basis are provided for the optimization of the whole virus vaccine virus titer, and important application prospects and innovative significance are provided in the biomedical field.

The invention relates to a steroid antiviral agent, wherein a steroid compound has a structure as the formula I. The antiviral agent includes one or more of the compound as the formula I, or a stereoisomer, a geometric isomer, a tautomer, a solvate, a pre-drug or a pharmaceutically-acceptable salt of the compound I as effective components. The compound I has quite strong inhibition activity on respiratory syncytial virus (RSV) in paramyxoviridae, and can be used as an antiviral medicine or a lead compound of the antiviral medicine.

Virus virions defective in F gene are successfully collected by using a Sendai virus genomic cDNA with deletion of F gene. Further, infectious viral particles defective in F gene are successfully constructed by using F-expression cells as helper cells. Also, virus virions defective in F gene and HN gene are successfully collected by using a virus genomic cDNA with deletion of both of F gene and HN gene. Further, infectious viral particles defective in F gene and HN gene are successfully produced by using F- and HN-expression cells as helper cells. A virus being defective in F gene and HN gene and having F protein is constructed by using F-expression cells as helper cells. Further, a VSV-G pseudo type virus is successfully constructed by using VSV-G-expression cells. Techniques for constructing these defective viruses contribute to the development of vectors of Paramyxoviridae usable in gene therapy.

A new isoform of 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate (Remdesivir) having increased water solubility is disclosed, along with methods for making the same. Also disclosed are solid and liquid pharmaceutical compositions suitable for treating viral infections such as Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, or Paramyxoviridae viral infections which contain an effective amount of Remdesivir prepared according to the inventive method and the use of those compositions for treating such viral infections.